11/28/2018. Proton Therapy for Liver Cancer: Who, Why, and How. Disclosures. Michael Chuong, MD. None
|
|
- Barry Fox
- 5 years ago
- Views:
Transcription
1 Proton Therapy for Liver Cancer: Who, Why, and How Michael Chuong, MD Disclosures None 1
2 Rationale for proton therapy Hepatic toxicity Biliary toxicity GI toxicity Potentially significant benefit especially for HCC patients } Less rationale Hepatic toxicity Radiation induced liver disease (RILD, classic) Anicteric hepatomegaly Ascites Elevated liver enzymes (ALP > AST/ALT) Non-classic RILD Elevation of transaminases Reactivation of Hepatitis B Liver function decline (CP) Risk of liver toxicity Diagnosis (HCC vs. non-hcc) Baseline liver function (CP A vs. B vs. C) RT dose Dose to non-target liver CP score decline at 3 months after SBRT Liver mets: <5% Early stage HCC: ~10% Advanced stage HCC (PVTT): ~30% CP B HCC: ~30-50% High dose to partial liver volumes is safe MEAN and LOW dose are most important Dawson et al. IJROBP
3 Grade 3+ liver enzyme increase Miften M, Dawson LA, M.D. 8 Radiation Dose-Volume Effects for Liver SBRT. AAPM Working Group on Biological Effects: SBRT Normal Tissue Complication Probability 6 fraction SBRT toxicity for metastases 81 patients with 1-6 liver mets Transient G1-2 hepatic toxicity within 3 months 61% transaminitis 28% albumin decline No grade 3-5 hepatic toxicity Higher risk if increased dose to 700 cc of non-targeted liver All patients No worsening Liver enz. Any worsening Liver enz. No. of patients (%) 81 (100) 32 (39.5) 49 (60.5) Prescription Dose Mean Gy (Range), 6 # 43 (28 60) 46 (28 60) 42 (28 60) Mean Liver Dose Mean Gy (Range) 16 (3 26) 15 (3 26) 17 (5.2 23) Dose to spared 700cc Mean Gy (range) 11 (0.3 29) 8.7 (0.3 25) 12.6 (0.6 29) Pts with 700cc 20Gy, 6 # % (ratio) 88 (71/81) 44 (31/71) 56 (40/71) Barry, PRO fraction SBRT toxicity for HCC: Toronto 102 patients All CP A 6 fractions to Gy Median tumor size 7.2 cm 29% developed worse CP score within 3 months after SBRT Bujold et al, JCO
4 QUANTEC liver constraints (5-6 fractions) HCC CP A Mean liver (minus GTV) <13-18 Gy >800 cc <18 Gy CP B Mean liver (minus GTV) <6 Gy Mets Mean liver (minus GTV) <15-20 Gy >700 cc <15 Gy Pan et al, IJROBP, 2009 VMAT PROTON LOW DOSE ZERO DOSE Kim, Acta Oncologica, 2017 Kim, Acta Oncologica,
5 V0-30 was significantly a/w liver function at 12 months after PBT preferred V0 <30% V0 was the most useful index for measurement of retention of normal liver function Mizumoto et al. IJROBP 2012 Proton therapy in Japan Igaki et al. Int J Clin Oncol, 2017 University of Tsukuba Prof Toshiyuki Okumura 5
6 66 Gy in 10 fractions Prof Toshiyuki Okumura Prof Toshiyuki Okumura Median follow up 55 months N=129 Child A 78%, B 22% Median tumor 3.9 cm (1-13.5) PVTT 12% Multiple tumors 26% Passive scattering Fiducials Gating CTV = GTV mm ITV = CTV + 5 mm PTV = ITV mm 6
7 Tsukuba long-term results Local control 5-yr 94% (stage A), 87% (B stage), 75% (C stage Overall survival 5-yr 69% (stage A), 66% (B stage), 25% (C stage) No grade 3 toxicity Large HCC Median, 11 cm (range, cm) Median, 72.6 GyE in 22 fractions No grade 3+ toxicity 2-year LC 87% Fig. 2. Local control rates in 22 patients with hepatocellular carcinoma exceeding 10 cm treated with proton beam therapy. Sugahara S, et al. Int J Radiat Oncol Biol Phys
8 Hypofractionation Tsukuba >2 cm from porta hepatis: 66 Gy(RBE) in 10 fxn <2 cm from porta hepatis: 72.6 Gy(RBE) in 22 fxn <2 cm from GI tract: 77 Gy in 35 fxn Loma Linda 63 Gy(RBE) in 15 fxn MGH/MDACC/PENN >2 cm from porta hepatis: 67.5 Gy(RBE) in 15 fxn <2 cm from porta hepatis: Gy(RBE) in 15 fxn Child Pugh change Mizumoto et al (IJROBP 2011) 9% increase score by 2 points after 6 months Kim et al (Radiother Oncol 2017) 2.4% increased score by 1 after 3 month Hong et al (JCO 2016) 3.6% increased class after 6 months PMH SBRT 29% increased class after 3 months 8
9 Group 1 = medically necessary When to use protons??? All HCC patients? RILD serious complication Protons provide optimal liver sparing Potential future liver-directed therapies Non-HCC patients? THERE ARE NO RANDOMIZED DATA 9
10 Pract Radiat Oncol. 2015; 5(4): Photons Protons Dome 3 cm Central 3 cm 3 cm Gandhi et al. Pract Radiat Oncol. 2015; 5(4):
11 2018 Miami Liver Proton Therapy Working Group Meeting Focused discussion on patient selection Larger tumors High tumor:normal liver Moderately to severely cirrhotic patients (CP-B/C) History of prior liver radiation (external or internal) RILD risk higher in CP-B+ patients University of Indiana 4/8 (50%) CP-B8+ pts developed progressive liver failure Fatal RILD in 2 of these patients (25%) Princess Margaret Hospital 29 CP-B/C pts (69% CP-B7), PVTT 76% CP score + 2 or more: 34% at 3 months The liver dose was limited in 89% of cases Andolino et al. Int J Radiat Oncol Biol Phys 2011 Culleton et al. Radiother Oncol 2014 Lasley et al. Pract Radiat Oncol
12 Safety of Protons for CP-B/C Patients Study # Pts CP Class RILD Definition Tsukuba CP-A 76% CP-B 22% Loma Linda 2 76 CP-A 29% CP-B 47% CP-C 24% CP score + 1 CP score + 2 AST, ALT, ALP, T-bili, albumin, INR 1 month RILD Rate Mean Liver (EQD 3 ) 1-yr 16% 1-yr 11% NR 0% NR MGH/ MDACC/ UPenn 3 44 CP-A 73% CP-B 21% CP class progression 3.6% 9.6 GyE 1 Mizumoto et al. Int J Radiat Oncol Biol Phys Bush et al. Cancer Hong et al. J Clin Oncol 2016 Proton therapy for cholangiocarcinoma? For unresectable ICC, chemotherapy is standard of care Gemcitabine/cisplatin per ABC-02 trial In patients who do not progress after chemotherapy, can proton therapy improve local control and survival? ABC-02 OS PFS Valle et al, NEJM
13 Ablative dose and survival Local Control (%) P= Time of Follow-Up (months) Overall Survival (%) P= Time of Follow-Up (months) Tao R, et al JCO 2016 Multi-institutional Phase 2 trial MGH/MDACC/UPENN HCC (n=44) and IHC (n=39) Sample size calculated to demonstrate >80% LC at 2 years Eligibility No cirrhosis or Child Pugh A/B ECOG PS 0-2 No extrahepatic disease Maximum tumor size 12 cm 15 fractions 67.5 GyE if > 2 cm from the porta hepatis GyE if within 2 cm of the porta hepatis Hong et al, JCO
14 Ablative proton therapy for liver mets? Jeong et al. Clin Can Res, pts Median 2.5 cm ( ) 23 pts had >6 cm tumor Median dose 40 GyE in 5 fractions (83% of >6 cm tumors received at least 40 GyE) No grade 3+ toxicity The motion problem Fundamentally the same between PBS and US/DS US / DS has more washout of the motion effect PBS is more susceptible to the motion effect, but this can be overcome Motion management Repainting Larger spot size From Tony Lomax 14
15 Repainting and gating Conclusions Why HCC: normal liver sparing Non-HCC: dose escalation/ablation Who HCC: larger tumor, more limited normal liver volume, worse baseline liver function Non-HCC: larger tumor with limited or no extrahepatic disease How Hypofractionation (smaller fraction size in close proximity to GI luminal structures) Mitigation of motion interplay effects 15
16 THANK YOU 16
Radiation Therapy for Liver Malignancies
Outline Radiation Therapy for Liver Malignancies Albert J. Chang, M.D., Ph.D. Department of Radiation Oncology, UCSF March 23, 2014 Rationale for developing liver directed therapies Liver directed therapies
More informationWhere are we with radiotherapy for biliary tract cancers?
Where are we with radiotherapy for biliary tract cancers? Professor Maria A. Hawkins Associate Professor in Clinical Oncology MRC Group Leader/Honorary Consultant Clinical Oncologist CRUK MRC Oxford Institute
More informationA prospective feasibility study of respiratory-gated proton beam therapy for liver tumors
A prospective feasibility study of respiratory-gated proton beam therapy for liver tumors The Harvard community has made this article openly available. Please share how this access benefits you. Your story
More informationNCCN Guidelines Update: Locoregional Treatment Approaches for Hepatocellular Carcinoma. Memorial Sloan Kettering Cancer Center. Anne M Covey, MD, FSIR
NCCN Guidelines Update: Locoregional Treatment Approaches for Hepatocellular Carcinoma Daniel T. Chang, MD Stanford Cancer Institute Anne Covey, MD Memorial Sloan Kettering Cancer Center Locoregional Therapy
More informationRole of SBRT in the management of lung and liver metastases. Ronan TANGUY, M.D. Radiation Oncologist
Role of SBRT in the management of lung and liver metastases Ronan TANGUY, M.D. Radiation Oncologist Oligometastatic RCC mrcc: Lung, Bone, Liver, Brain (Schlesinger-Raab, EJC2008) Targeted therapies Objective
More informationProton Beam Therapy for Hepatocellular Carcinoma. Li Jiamin, MD Wanjie Proton Therapy Center
Proton Beam Therapy for Hepatocellular Carcinoma Li Jiamin, MD Wanjie Proton Therapy Center 1 1 Hepatocelluar carcinoma (HCC) is one of the most common cancers worldwide It is the eighth most common neoplasm
More informationRadiotherapy for liver cancer
Received: 7 November 2015 Accepted: 10 March 2016 DOI: 10.1002/jgf2.19 REVIEW ARTICLE Radiotherapy for liver cancer Nobuyoshi Fukumitsu MD Toshiyuki Okumura MD Hideyuki Sakurai MD Proton Medical Research
More informationStereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V.
Stereotactic Body Radiotherapy (SBRT) For HCC T A R E K S H O U M A N P R O F. R A D I A T I O N O N C O L O G Y N C I, C A I R O U N I V. Hepatocellular carcinoma (HCC), is a major health problem worldwide.
More informationTargeted Radiation +/- Biologics News Briefing
Targeted Radiation +/- Biologics News Briefing Wednesday, October 31, 2012 7:00 a.m. 7:45 a.m. Catherine Park, MD Vice-chairman of the ASTRO Education Committee Eric Chang, MD ASTRO Annual Meeting Scientific
More informationFegato le)eratura ed esperienza clinica. A Guarneri
Fegato le)eratura ed esperienza clinica A Guarneri EASL EORTC Clinical Practice GuidelinesJ Hepatology 2012 HEPATOCELLULAR CARCINOMA Classic Radia*on-Induced Liver Disease (RILD) Clinical syndrome of
More informationRadiation Therapy 2/20/2014. Disclosures. Therapeutic Ratio. Rules in Radiotherapy. Radiation oncology is a technology based specialty
Disclosures Proton therapy for Gastrointestinal tumors Ed Kim has no financial relationships, arrangements, or affiliations with commercial entities. Ed Kim, MD February 22 2014 Radiation Therapy Therapeutic
More informationSBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment
SBRT and hypofractionated RT for HCC patients with varying degrees of hepatic impairment Nima Nabavizadeh, MD Assistant Professor Division Leader Hematologic Malignancies Co-division Leader Gastrointestinal
More informationAblative Radiation Therapy For Inoperable Cholangiocarcinoma. Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology
Ablative Radiation Therapy For Inoperable Cholangiocarcinoma Christopher H. Crane, M.D. Program Director, GI Section Department of Radiation Oncology Facts about radiation treatment High doses (2x the
More information8/3/2016. Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients. Acknowledgement. Overview
Implementation of Pencil Beam Scanning (PBS) Proton Therapy Treatment for Liver Patients Liyong Lin, PhD, Assistant Professor Department of Radiation Oncology University of Pennsylvania Acknowledgement
More information8/1/2016. Motion Management for Proton Lung SBRT. Outline. Protons and motion. Protons and Motion. Proton lung SBRT Future directions
Motion Management for Proton Lung SBRT AAPM 2016 Outline Protons and Motion Dosimetric effects Remedies and mitigation techniques Proton lung SBRT Future directions Protons and motion Dosimetric perturbation
More informationAndrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Associate Professor Department tof fradiation Oncology M.D. Anderson Cancer Center Seungtaek Choi, MD Assistant Professor Department tof fradiation
More informationCisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer. Valle J et al. N Engl J Med 2010;362(14):
Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer Valle J et al. N Engl J Med 2010;362(14):1273-81. Introduction > Biliary tract cancers (BTC: cholangiocarcinoma, gall bladder cancer,
More informationFive Years Comprehensive Experience in Proton Radiotherapy in PMRC Tsukuba
PTCOG 47 Jacksonville, Florida 2008.05.22 Five Years Comprehensive Experience in Proton Radiotherapy in PMRC Tsukuba Koji Tsuboi M.D., Ph.D. Proton Medical Research Center, University of Tsukuba, JAPAN
More informationThe role of Radiation Oncologist: Hi-tech treatments for liver metastases
The role of Radiation Oncologist: Hi-tech treatments for liver metastases Icro Meattini, MD Radiotherapy-Oncology Unit AOU Careggi Hospital Florence University, Italy Liver Metastases - Background The
More informationStatus of H 1 and C 12
Status of H 1 and C 12 Herman Suit No Conflict of Interest 1 Goal of a New Treatment Modality Tumor Control Probability or No in Complication Rate 2 Truism No Advantage to: any Patient for any Radiation
More informationEDUCATIONAL COURSE TU-A-BRB-1
Brian D. Kavanagh, MD, MPH Department of Radiation Oncology University of Colorado School of Medicine EDUCATIONAL COURSE TU-A-BRB-1 Physics and Dosimetry of SBRT Part III: Planning Case Studies 3 of the
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationLiver Radiation: Review of Pertinent Anatomy and Physiology, Functional Imaging, and Potential Future Direction
Liver Radiation: Review of Pertinent Anatomy and Physiology, Functional Imaging, and Potential Future Direction David E. Long, MD Radiation Oncology, PGY3 Indiana University School of Medicine AAMD 42nd
More informationPancreatic Cancer and Radiation Therapy
Pancreatic Cancer and Radiation Therapy Why? Is there a role for local therapy with radiation in a disease with such a high rate of distant metastases? When? Resectable Disease Is there a role for post-op
More informationTHE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA. TIMUR MITIN, MD, PhD
THE ROLE OF RADIATION THERAPY IN MANAGEMENT OF PANCREATIC ADENOCARCINOMA TIMUR MITIN, MD, PhD RESECTABLE DISEASE MANAGEMENT: RESECTABLE DISEASE Resection offers the only possibility of long term survival
More informationRadiation Biology & Future Trends of SBRT. SBRT: radiobiological modeling University of Colorado SBRT: snapshot of the program
Radiation Biology & Future Trends of SBRT Brian D. Kavanagh, MD, MPH Department of Radiation Oncology University of Colorado Comprehensive Cancer Center Radiation Biology & Future Trends of SBRT SBRT:
More informationProton Therapy for tumors of the skull base - RESULTS. Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY
Proton Therapy for tumors of the skull base - RESULTS Eugen B. Hug, MD Medical Director, ProCure Proton Therapy Centers, NY Petroclival Chondrosarcoma: 68 72 Gy(RBE) at 1.8 or 2.0 Gy(RBE) GTV: 70.2 Gy(RBE)
More informationNCCN Guidelines for Hepatobiliary Cancers V Web teleconference on 10/24/17
Guideline Page and Request HCC-4 the American Society of Radiation Oncology (ASTRO): We recommend further clarification of the eligibility criteria for surgical resection and liver transplantation, respectively.
More informationToramatsu et al. Radiation Oncology 2013, 8:48
Toramatsu et al. Radiation Oncology 2013, 8:48 RESEARCH Open Access What is the appropriate size criterion for proton radiotherapy for hepatocellular carcinoma? A dosimetric comparison of spot-scanning
More informationESMO Conference: 11th World Congress on Gastrointestinal Cancer June June
ESMO Conference: 11th World Congress on Gastrointestinal Cancer June 24 2009 - June 27 2009 External and Internal Radiation Therapy for Liver Cancer Disclosures Research Grants: Elekta, Bayer Laura A.
More informationChapter 2 Modern Radiation Therapy Approaches: Targeted and Ablative Strategies
Chapter 2 Modern Radiation Therapy Approaches: Targeted and Ablative Strategies Theodore S. Hong Introduction Modern radiation therapy is a therapeutic cancer modality that can achieve local and regional
More informationAdvances in external beam radiotherapy
International Conference on Modern Radiotherapy: Advances and Challenges in Radiation Protection of Patients Advances in external beam radiotherapy New techniques, new benefits and new risks Michael Brada
More informationHepatocellular carcinoma (HCC)
Stereotactic body radiation therapy (SBRT) for early-stage primary liver cancer (HCC) Raymond A. Schulz, MSc, Calvin Huntzinger, MSc, Seth Blacksburg, MD, MBA, and Kenneth Rosenzweig, MD Hepatocellular
More informationDOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES
DOES RADIOTHERAPY TECHNIQUE / DOSE / FRACTIONATION REALLY MATTER? YES Marco Krengli Radiotherapy, Department of Translational Medicine, University of Piemonte Orientale A. Avogadro THE STANDARD OF CARE
More informationProton therapy for hepatocellular carcinoma
Review Article Proton therapy for hepatocellular carcinoma Ted C. Ling, Joseph I. Kang, David A. Bush, Jerry D. Slater, Gary Y. Yang Department of Radiation Medicine, Loma Linda University Medical Center,
More informationPortal Vein Invasion and the Role of Liver Directed Therapy. Matthew S Johnson MD FSIR Indiana University May 6, 2016
Portal Vein Invasion and the Role of Liver Directed Therapy Matthew S Johnson MD FSIR Indiana University May 6, 2016 Matthew Johnson, M.D., FSIR Stock: Endoshape Consultant/Advisory Board: Bayer, BTG,
More informationState-of-the-art proton therapy: The physicist s perspective
State-of-the-art proton therapy: Tony Lomax, Centre for Proton Radiotherapy, Paul Scherrer Institute, Switzerland Overview of presentation 1. State-of-the-art proton delivery 2. Current challenges 3. New
More informationProton beam therapy for liver tumors
Proton beam therapy for liver tumors University of Tsukuba, Japan Hideyuki Sakurai, Toshiyuki Okumura, Nobuyoshi Fukumitsu, Hitoshi Ishikawa, Kayoko Ohnishi, Masashi Mizumoto, Keiko Murofushi, Haruko Numajiri,
More informationFuture Directions in Prostate Cancer: The Case for Protons. John J. Coen, MD Helen & Harry Gray Cancer Center
Future Directions in Prostate Cancer: The Case for Protons John J. Coen, MD Helen & Harry Gray Cancer Center November 14, 2012 Protons and prostate cancer Early proton experience at the MGH The case for
More informationPo-Ming Wang 1, Wei-Chung Hsu 1,2, Na-Na Chung 1, Feng-Ling Chang 1, Chin-Jyh Jang 1, Antonella Fogliata 3, Marta Scorsetti 4 and Luca Cozzi 3*
Wang et al. Radiation Oncology 2014, 9:18 RESEARCH Open Access Feasibility of stereotactic body radiation therapy with volumetric modulated arc therapy and high intensity photon beams for hepatocellular
More informationCheng-En Hsieh 1,2, Ji-Hong Hong 1,3, Chen-Chun Lin 4, Ching-Hsin Lee 1, Sheng-Ping Hung 1, Chen-Yu Chou 1, Chien-Ming Chen 5, Jeng-Hwei Tseng 5
Case Report Page 1 of 6 Complete response of unresectable icteric-type hepatocellular carcinoma to hypofractionated proton beam therapy with concurrent plus adjuvant sorafenib: a case report Cheng-En Hsieh
More informationClinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology
Clinical Aspects of SBRT in Abdominal Regions Brian D. Kavanagh, MD, MPH University of Colorado Department of Radiation Oncology Abdominal SBRT: Clinical Aspects Rationales for liver and pancreas SBRT
More informationCPT code semantics 8/18/2011. SBRT Planning Case Studies. Spectrum of applications of SBRT. itreat
Spectrum of applications of SBRT EDUCATIONAL COURSE Physics and Dosimetry of SBRT Part III: Planning Case Studies Brian D. Kavanagh, MD, MPH Department of Radiation Oncology University of Colorado School
More informationTreatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer
Treatment results of proton beam therapy with chemo-radiotherapy for stage I-III esophageal cancer Nobukazu Fuwa 1, Akinori Takada 2 and Takahiro Kato 3 1;Departments of Radiology, Hyogo Ion Beam Medical
More informationThe Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology
The Evolution of SBRT and Hypofractionation in Thoracic Radiation Oncology (specifically, lung cancer) 2/10/18 Jeffrey Kittel, MD Radiation Oncology, Aurora St. Luke s Medical Center Outline The history
More informationNews Release. Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012
News Release Embargoed until 1:45 p.m. ET, Sunday, October 28, 2012 Contact: Michelle Kirkwood 703-286-1600 michellek@astro.org Concurrent use of sorafenib and stereotactic body radiotherapy for advanced
More informationReference: NHS England B01X26
Clinical Commissioning Policy Proposition: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England
More informationReference: NHS England: 16022/P
Clinical Commissioning Policy: The use of Stereotactic Ablative Radiotherapy (SABR) as a treatment option for patients with Hepatocellular carcinoma or Cholangiocarcinoma Reference: NHS England: 16022/P
More informationRadiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali
Radiotherapy Planning (Contouring Lung Cancer for Radiotherapy dose prescription) Dr Raj K Shrimali Let us keep this simple and stick to some basic rules Patient positioning Must be reproducible Must be
More informationAdvances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展
Advances in radiation oncology in the management of soft tissue sarcoma 放疗于治疗肉瘤的最新发展 Brian O Sullivan Bartley-Smith / Wharton Chair Professor, Department of Radiation Oncology The Princess Margaret / University
More informationChapter 13 Proton Therapy for Thoracoabdominal Tumors
Chapter 13 Proton Therapy for Thoracoabdominal Tumors Hideyuki Sakurai, Toshiyuki Okumura, Shinji Sugahara, Hidetsugu Nakayama, and Koichi Tokuuye Abstract In advanced-stage disease of certain thoracoabdominal
More informationSBRT in early stage NSCLC
SBRT in early stage NSCLC Optimal technique and tumor dose Frank Zimmermann Clinic of Radiotherapy and Radiation Oncology University Hospital Basel Petersgraben 4 CH 4031 Basel radioonkologiebasel.ch Techniques
More informationReirradiazione. La radioterapia stereotassica ablativa: torace. Pierluigi Bonomo Firenze
Reirradiazione La radioterapia stereotassica ablativa: torace Pierluigi Bonomo Firenze Background Stage III NSCLC isolated locoregional recurrence in 25% of pts mostly unresectable; low RR with 2 nd line
More informationHepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities
CME International Journal of Radiation Oncology biology physics www.redjournal.org Critical Review Hepatocellular Carcinoma Radiation Therapy: Review of Evidence and Future Opportunities Jonathan Klein,
More informationClinical Session 3 Liver Cancer. Toshiyuki Okumura M.D. Takayuki Hashimoto M.D. Proton Medical Research Center University of Tsukuba
Clinical Session 3 Liver Cancer Toshiyuki Okumura M.D. Takayuki Hashimoto M.D. Proton Medical Research Center University of Tsukuba Liver Cancer: Topics for today Anatomy Epidemiology Risk factors of liver
More informationStereotactic body radiation therapy for primary hepatic malignancies and liver metastases
Review Article Stereotactic body radiation therapy for primary hepatic malignancies and liver metastases Anthony J. Paravati 1, Erin Healy 2, James D. Murphy 1, William Song 1, Jona Hattangadi-Gluth 1
More informationOverview. Proton Therapy in lung cancer 8/3/2016 IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS
IMPLEMENTATION OF PBS PROTON THERAPY TREATMENT FOR FREE BREATHING LUNG CANCER PATIENTS Heng Li, PhD Assistant Professor, Department of Radiation Physics, UT MD Anderson Cancer Center, Houston, TX, 773
More informationES-SCLC Joint Case Conference. Anthony Paravati Adam Yock
ES-SCLC Joint Case Conference Anthony Paravati Adam Yock Case 57 yo woman with 35 pack year smoking history presented with persistent cough and rash Chest x-ray showed a large left upper lobe/left hilar
More informationReview of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for
Review of Workflow NRG (RTOG) 1308: Phase III Randomized Trial Comparing Overall Survival after Photon versus Proton Chemoradiation Therapy for Inoperable Stage II-IIIB NSCLC 1 Co-Chairs Study Chair: Zhongxing
More informationSacral Chordoma: The Loma Linda University Radiation Medicine Experience. Kevin Yiee MD, MPH Resident Physician
Sacral Chordoma: The Loma Linda University Radiation Medicine Experience Kevin Yiee MD, MPH Resident Physician What is a chordoma? 1 st chordoma discovered in clivus by Virchow and Luschka 1856 Rare tumor
More informationApplication of Implanted Markers in Proton Therapy. Course Outline. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint
Application of Implanted Markers in Proton Therapy Sung Yong Park, Ph.D. McLaren Proton Therapy Center Karmanos Cancer Institute McLaren - Flint AAPM 2016, SAM Therapy Educational Course, 2016.08.04. Course
More informationExtracranial SBRT: from technical availabilities to routine clinical opportunities. Pr. Eric F. LARTIGAU Centre Oscar Lambret, Lille France
Extracranial SBRT: from technical availabilities to routine clinical opportunities Pr. Eric F. LARTIGAU Centre Oscar Lambret, Lille France Disclosure consultant for : Accuray, Amgen, Astellas, Merck-Serono
More informationReport on Radiation Disaster Recovery Studies
Report on Radiation Disaster Recovery Studies Course: Radiation Disaster Medicine Name: Uranchimeg Tsegmed Radiation Disaster Recovery Studies Nowadays, applications of nuclear technology in different
More information肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部
肺癌放射治療新進展 Recent Advance in Radiation Oncology in Lung Cancer 許峰銘成佳憲國立台灣大學醫學院附設醫院腫瘤醫學部 Outline Current status of radiation oncology in lung cancer Focused on stage III non-small cell lung cancer Radiation
More informationTecniche Radioterapiche U. Ricardi
Tecniche Radioterapiche U. Ricardi UNIVERSITA DEGLI STUDI DI TORINO Should we always rely on stage? T4N0M0 Stage IIIB T2N3M0 Early stage NSCLC The treatment of choice for early-stage NSCLC is anatomic
More informationNon-small cell lung cancer (NSCLC) is a common cause
ORIGINAL ARTICLE Results of Proton Beam Therapy without Concurrent Chemotherapy for Patients with Unresectable Stage III Non-small Cell Lung Cancer Yoshiko Oshiro, MD,* Masashi Mizumoto, MD,* Toshiyuki
More informationThe Physics of Oesophageal Cancer Radiotherapy
The Physics of Oesophageal Cancer Radiotherapy Dr. Philip Wai Radiotherapy Physics Royal Marsden Hospital 1 Contents Brief clinical introduction Imaging and Target definition Dose prescription & patient
More informationSPECT-Based Radiation Therapy and Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Sized 14 cm or Greater
SPECT-Based Radiation Therapy and Transcatheter Arterial Chemoembolization for Unresectable Hepatocellular Carcinoma Sized 14 cm or Greater Shintaro Shirai 1, Morio Sato 1, Yasutaka Noda 1, Kazushi Kishi
More informationWould SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy?
Would SBRT Hypofractionated Approach Be as Good? Then Why Bother With Brachytherapy? Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan Disclosure
More informationPo-Ming Wang 1, Wei-Chung Hsu 1,2, Na-Na Chung 1, Feng-Ling Chang 1, Antonella Fogliata 3* and Luca Cozzi 3
Wang et al. Radiation Oncology 2012, 7:207 RESEARCH Open Access Radiation treatment with volumetric modulated arc therapy of hepatocellular carcinoma patients. Early clinical outcome and toxicity profile
More informationLinac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR
Linac or Non-Linac Demystifying And Decoding The Physics Of SBRT/SABR PhD, FAAPM, FACR, FASTRO Department of Radiation Oncology Indiana University School of Medicine Indianapolis, IN, USA Indra J. Das,
More informationStereotactic radiotherapy
Stereotactic radiotherapy Influence of patient positioning and fixation on treatment planning - clinical results Frank Zimmermann Institut für Radioonkologie Universitätsspital Basel Petersgraben 4 CH
More informationClinical Aspects of Proton Therapy in Lung Cancer. Joe Y. Chang, MD, PhD Associate Professor
Clinical Aspects of Proton Therapy in Lung Cancer Joe Y. Chang, MD, PhD Associate Professor Clinical Service Chief Thoracic Radiation Oncology Lung Cancer Basic Factors No. 1 cancer killer 161,840 patients
More informationProtons for Head and Neck Cancer. William M Mendenhall, M.D.
Protons for Head and Neck Cancer William M Mendenhall, M.D. Protons for Head and Neck Cancer Potential Advantages: Reduce late complications via more conformal dose distributions Likely to be the major
More informationRadiation therapy for hepatobiliary malignancies
Review Article Radiation therapy for hepatobiliary malignancies Jonathan W. Lischalk, Michael C. Repka, Keith Unger Department of Radiation Medicine, Georgetown University Hospital, Washington, DC, USA
More informationDisclosures. Proton therapy advantages. Why are comparing therapies difficult? Proton Therapy for Low Risk Prostate Cancer
Proton Therapy for Low Risk Prostate Cancer Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments Andrew K. Lee, MD, MPH Associate Professor
More informationDisclosures. Overview 8/3/2016. SRS: Cranial and Spine
SRS: Cranial and Spine Brian Winey, Ph.D. Department of Radiation Oncology Massachusetts General Hospital Harvard Medical School Disclosures Travel and research funds from Elekta Travel funds from IBA
More informationStereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors
Stereotactic MR-guided adaptive radiation therapy (SMART) for locally advanced pancreatic tumors Anna Bruynzeel, Radiation Oncologist VU University Medical Center, Amsterdam, The Netherlands Current standard
More informationMight Adaptive Radiotherapy in NSCLC be feasible in clinical practice?
Might Adaptive Radiotherapy in NSCLC be feasible in clinical practice? E.Molfese, P.Matteucci, A.Iurato, L.E.Trodella, A.Sicilia, B.Floreno, S.Ramella, L.Trodella Radioterapia Oncologica, Università Campus
More informationNCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) BONE (Version , 03/28/18)
BONE (Version 2.2018, 03/28/18) NCCN GUIDELINES ON PROTON THERAPY (AS OF 4/23/18) Radiation Therapy Specialized techniques such as intensity-modulated RT (IMRT); particle beam RT with protons, carbon ions,
More information8/4/2016. Effect of underdosage and overdosage. Photon versus Proton Therapy: Have we reached the limit? Effect. Tumor Dose.
Effect 8/4/2016 Photon versus Proton Therapy: Have we reached the limit? American Association of Medical Physics Annual Meeting Washington, DC Stephen M Hahn August 4, 2016 Effect of underdosage and overdosage
More informationPancreas SBRT. Rakendu Shukla, MD KyNam Nguyen, MD Brandon Dyer, MD Faculty Advisor: Arta Monjazeb, MD PhD University of California - Davis
Pancreas SBRT Rakendu Shukla, MD KyNam Nguyen, MD Brandon Dyer, MD Faculty Advisor: Arta Monjazeb, MD PhD University of California - Davis December 19, 2018 Clinical Presentation 48 year old woman initially
More informationHow can we Personalize RT as part of Breast-Conserving Therapy?
How can we Personalize RT as part of Breast-Conserving Therapy? Jay R. Harris Dana-Farber Cancer Institute (DFCI) Brigham and Women s Hospital (BWH) Harvard Medical School Disclosures I have no COI disclosures
More informationPitfalls in SBRT Treatment Planning for a Moving Target
Pitfalls in SBRT Treatment Planning for a Moving Target Cynthia F. Chuang, Ph.D. Department of Radiation Oncology University of California-San Francisco I have no conflicts of interests to disclose In
More informationCyberKnife SBRT for Prostate Cancer
CyberKnife SBRT for Prostate Cancer Robert Meier, MD Swedish Radiosurgery Center Swedish Cancer Institute Seattle, WA 2017 ESTRO Meeting, Vienna Austria 5-year safety, efficacy & quality of life outcomes
More informationSTAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY?
STAGE I INOPERABLE NSCLC RADIOFREQUENCY ABLATION OR STEREOTACTIC BODY RADIOTHERAPY? MICHAEL LANUTI, MD American Association of Thoracic Surgeons Minneapolis, MN 2013 STAGE I INOPERABLE NSCLC RADIOFREQUENCY
More informationObjectives. Image-Guided RT: Process. kv CBCT Novel Clinical Applications and Future Directions. Standard Clinical Uses. Novel Applications.
kv Novel Clinical Applications and Future Directions Douglas J. Moseley PhD, DABR Department of Radiation Oncology University of Toronto Radiation Medicine Program Princess Margaret Hospital Objectives
More informationDisclosure SBRT. SBRT for Spinal Metastases 5/2/2010. No conflicts of interest. Overview
Stereotactic Body Radiotherapy (SBRT) for Recurrent Spine Tumors Arjun Sahgal M.D., F.R.C.P.C. Assistant Professor Princess Margaret Hospital Sunnybrook Health Sciences Center University of Toronto Department
More informationTreatment Planning (Protons vs. Photons)
Treatment Planning Treatment Planning (Protons vs. Photons) Acquisition of imaging data Delineation of regions of interest Selection of beam directions Dose calculation Optimization of the plan Hounsfield
More informationTreatment Planning & IGRT Credentialing for NRG SBRT Trials
Treatment Planning & IGRT Credentialing for NRG SBRT Trials Hania Al Hallaq, Ph.D. Department of Radiation & Cellular Oncology The University of Chicago Learning Objectives Explain rationale behind credentialing
More informationProton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas
Proton Radiation Therapy for Osteosarcomas, Chondrogenic Tumors and Soft Tissue Sarcomas Eugen B. Hug Center for Proton Radiation Therapy Paul Scherrer Institute Is there a place for Proton/Particle Radiotherapy
More informationImplementing New Technologies for Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy
Implementing New Technologies for Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy Implementation of radiosurgery and SBRT requires a fundamentally sound approach Errors don t blur out
More informationONCOLOGY LETTERS 10: , 2015
ONCOLOGY LETTERS 10: 201-205, 2015 Proton beam therapy for locally advanced and unresectable (T4bN0M0) squamous cell carcinoma of the ethmoid sinus: A report of seven cases and a literature review TAKASHI
More informationEffectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience
Effectiveness and Safety of Spot Scanning Proton Radiation Therapy for Skull Base Tumors: First Long Term Report of the PSI Experience Carmen Ares, Antony J Lomax, Eugen B Hug, Alessandra Bolsi, Beate
More informationRole of protons, heavy ions and BNCT in brain tumors
Role of protons, heavy ions and BNCT in brain tumors Prof G K Rath Head, NCI (AIIMS-2) Chief, Dr. BRA IRCH, Professor Radiation Oncology All India Institute of Medical Sciences, New Delhi 1 Overview of
More informationRob Glynne-Jones Mount Vernon Cancer Centre
ESMO Preceptorship Programme Colorectal Cancer Barcelona October 2017 Interventional radiology and stereotactic radiotherapy Rob Glynne-Jones Mount Vernon Cancer Centre My Disclosures: last 5 years Speaker:
More information4/25/2018. Proton Therapy for Head and Neck Cancer: The Future is Now. Disclosures. Overview. Physical limitations of photons
Proton Therapy for Head and Neck Cancer: The Future is Now Michael Chuong, MD Radiation Oncologist Disclosures None Overview Physical limitations of photons Dosimetric/clinical proton data for HNC Proton
More informationProton Therapy for Prostate Cancer. Andrew K. Lee, MD, MPH Director Proton Therapy Center
Proton Therapy for Prostate Cancer Andrew K. Lee, MD, MPH Director Proton Therapy Center Disclosures No relevant financial disclosures This presentation will not discuss off-label or investigational treatments
More informationSIRT Dosimetry: Sometimes Less Is More
SIRT Dosimetry: Sometimes Less Is More Navesh K. Sharma, DO, PhD Assistant Professor, Departments of Radiation Oncology, Diagnostic Radiology and Nuclear Medicine Medical Director, Radiation Oncology,
More informationUpdate on Limited Small Cell Lung Cancer. Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver
Update on Limited Small Cell Lung Cancer Laurie E Gaspar MD, MBA Prof/Chair Radiation Oncology University of Colorado Denver Objectives - Limited Radiation Dose Radiation Timing Radiation Volume PCI Neurotoxicity
More information